Professional Documents
Culture Documents
Department of Medicine, University of Colorado, Denver, Colorado; 2Denver Public Health Department, Denver, Colorado; 3Department
of Medicine, Columbia University College of Physicians and Surgeons, New York, New York; and 4Departments of Epidemiology and
Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York
Nontuberculous
Mycobacterial Disease
The Journal published two clinical studies
in 2013 of patients in the United States with
TB
Basic Science
( Received in original form February 3, 2014; accepted in final form March 7, 2014 )
Correspondence and requests for reprints should be addressed to Neil W. Schluger, M.D., Columbia University Medical Center, 622 West 168th Street,
New York, NY 10032. E-mail: ns311@cumc.columbia.edu
Am J Respir Crit Care Med Vol 189, Iss 8, pp 894898, Apr 15, 2014
Copyright 2014 by the American Thoracic Society
DOI: 10.1164/rccm.201402-0210UP
Internet address: www.atsjournals.org
894
American Journal of Respiratory and Critical Care Medicine Volume 189 Number 8 | April 15 2014
American Journal of Respiratory and Critical Care Medicine Volume 189 Number 8 | April 15 2014
897
R, et al. S100A8/A9
proteins mediate neutrophilic inammation and lung pathology during
tuberculosis. Am J Respir Crit Care Med 2013;188:11371146.
6. Day CL, Tameris M, Mansoor N, van Rooyen M, de Kock M, Geldenhuys
H, Erasmus M, Makhethe L, Hughes EJ, Gelderbloem S, et al.
Induction and regulation of T-cell immunity by the novel tuberculosis
vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med
2013;188:492502.
7. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart
S, Shea JE, McClain JB, Hussey GD, Hanekom WA, et al.; MVA85A
020 Trial Study Team. Safety and efcacy of MVA85A, a new
tuberculosis vaccine, in infants previously vaccinated with BCG:
a randomised, placebo-controlled phase 2b trial. Lancet 2013;381:
10211028.
8. Teles RM, Graeber TG, Krutzik SR, Montoya D, Schenk M, Lee DJ,
Komisopoulou E, Kelly-Scumpia K, Chun R, Iyer SS, et al. Type I
interferon suppresses type II interferon-triggered human antimycobacterial responses. Science 2013;339:14481453.
9. Suwanpimolkul G, Jarlsberg LG, Grinsdale JA, Osmond D, Kawamura
LM, Hopewell PC, Kato-Maeda M. Molecular epidemiology of
tuberculosis in foreign-born persons living in San Francisco. Am J
Respir Crit Care Med 2013;187:9981006.
10. Moonan PK, Teeter LD, Salcedo K, Ghosh S, Ahuja SD, Flood J,
Graviss EA. Transmission of multidrug-resistant tuberculosis in the
USA: a cross-sectional study. Lancet Infect Dis 2013;13:777784.
11. Jones-Lopez
898
A. Assessment of clofazimine
activity in a second-line regimen for tuberculosis in mice. Am J
Respir Crit Care Med 2013;188:608612.
24. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR.
Acceleration of tuberculosis treatment by adjunctive therapy with
verapamil as an efux inhibitor. Am J Respir Crit Care Med 2013;188:
600607.
25. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert
O, Edelstein PH, Cosma CL, Ramakrishnan L. Drug tolerance in
replicating mycobacteria mediated by a macrophage-induced efux
mechanism. Cell 2011;145:3953.
26. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M,
Bara W, Mungofa S, Pai M, Hoelscher M, et al.; TB-NEAT team.
Feasibility, accuracy, and clinical effect of point-of-care Xpert
Mtb/Rif testing for tuberculosis in primary-care settings in Africa:
a multicentre, randomised, controlled trial. Lancet 2014;383:
424435.
27. Frick M, Jimenez-Levi
American Journal of Respiratory and Critical Care Medicine Volume 189 Number 8 | April 15 2014